SEARCH WITHIN CONTENT
VOLUME 6 , ISSUE 2 ( July-December, 2022 ) > List of Articles
Parminder Singh, Manavdeep Kaur, Dinesh Kumar, Harsimran Kaur
Keywords : Ankylosing spondylitis, Pott's spine, Tofacitinib
Citation Information : Singh P, Kaur M, Kumar D, Kaur H. Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy. Curr Trends Diagn Treat 2022; 6 (2):37-38.
License: CC BY-NC 4.0
Published Online: 21-12-2022
Copyright Statement: Copyright © 2022; The Author(s).
Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton and peripheral joints. It is immune-mediated common in the second and third decades having symptoms such as sacroiliitis, synovitis, and difficulty in movement of the spine. It is treated with non-steroidal anti-inflammatory drugs (NSAIDs), JAK 2 inhibitors, and other biologicals such as infliximab and etanercept. This is the case report of a 24-year-old male student who presented with lower backache, and morning stiffness which improved with activity. On investigation, his HLA B 27 was positive and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were raised. He was treated with tofacitinib for 1 year, later he developed pott's spine as its side effect. This case report represents the rare side effect of tofacitinib as pott's spine.